| Full text | |
| Author(s): |
Grabarz, Felipe
[1, 2]
;
Lopes, Alexandre Paulo Yague
[1]
;
Barbosa, Flavia Ferreira
[2, 3]
;
Barazzone, Giovana Cappio
[1]
;
Santos, Jademilson Celestino
[1]
;
Botosso, Viviane Fongaro
[4]
;
Jorge, Soraia Attie Calil
[5]
;
Nascimento, Ana Lucia Tabet Oller
[1]
;
Astray, Renato Mancini
[3]
;
Goncalves, Viviane Maimoni
[1]
Total Authors: 10
|
| Affiliation: | [1] Inst Butantan, Lab Desenvolvimento Vacinas, BR-05503900 Sao Paulo - Brazil
[2] Univ Sao Paulo, Programa Interunidades Biotecnol, BR-05508060 Sao Paulo - Brazil
[3] Inst Butantan, Lab Multiproposito Viral, BR-05503900 Sao Paulo - Brazil
[4] Inst Butantan, Lab Virol, BR-05503900 Sao Paulo - Brazil
[5] Inst Butantan, Lab Biotecnol Viral, BR-05503900 Sao Paulo - Brazil
Total Affiliations: 5
|
| Document type: | Journal article |
| Source: | LIFE-BASEL; v. 11, n. 6 JUN 2021. |
| Web of Science Citations: | 0 |
| Abstract | |
Biopharmaceutical production is currently a multibillion-dollar industry with high growth perspectives. The research and development of biologically sourced pharmaceuticals are extremely important and a reality in our current healthcare system. Interferon alpha consensus (cIFN) is a non-natural synthetic antiviral molecule that comprises all the most prevalent amino acids of IFN-alpha into one consensus protein sequence. For clinical use, cIFN is produced in E. coli in the form of inclusion bodies. Here, we describe the use of two solubility tags (Fh8 and DsbC) to improve soluble cIFN production. Furthermore, we analyzed cIFN production in different culture media and temperatures in order to improve biopharmaceutical production. Our results demonstrate that Fh8-cIFN yield was improved when bacteria were cultivated in autoinduction culture medium at 30 degrees C. After hydrolysis, the recovery of soluble untagged cIFN was 58% from purified Fh8-cIFN molecule, fourfold higher when compared to cIFN recovered from the DsbC-cIFN, which achieved 14% recovery. The biological activity of cIFN was tested on in vitro model of antiviral effect against Zika, Mayaro, Chikungunya and SARS-CoV-2 virus infection in susceptible VERO cells. We show, for the first time, that cIFN has a potent activity against these viruses, being very low amounts of the molecule sufficient to inhibit virus multiplication. Thus, this molecule could be used in a clinical approach to treat Arboviruses and SARS-CoV-2. (AU) | |
| FAPESP's process: | 14/50981-0 - Search for surface proteins among the genome sequences of Leptospira interrogans: functional and immunological characterization to understanding mechanisms involved in the bacterial pathogenesis |
| Grantee: | Ana Lucia Tabet Oller do Nascimento |
| Support Opportunities: | Research Projects - Thematic Grants |
| FAPESP's process: | 16/50413-8 - Pulmonary delivery of a targeted mucosal nanocarrier vaccine for pneumonia |
| Grantee: | Viviane Maimoni Gonçalves |
| Support Opportunities: | Regular Research Grants |